Inozyme plans $75m IPO as it heads for clinic with rare bone diseases drugUS biotech Inozyme Pharma is the latest to jump on to the IPO bandwagon, setting terms for a Share XInozyme plans $75m IPO as it heads for clinic with rare bone diseases drughttps://pharmaphorum.com/news/inozyme-plans-75-ipo-as-it-heads-for-clinic-with-rare-bone-diseases-drug/
Poseida Therapeutics aims for $115m stock market launch to fund CAR-T R&DCalifornia biotech Poseida Therapeutics has become the latest biotech to hit the IPO trial after a string of launches last Share XPoseida Therapeutics aims for $115m stock market launch to fund CAR-T R&Dhttps://pharmaphorum.com/news/poseida-therapeutics/
Royalty Pharma shares surge 59% after $2.2 billion IPOBiopharma initial public offerings are back with a bang after a coronavirus pandemic lull, as Royalty Pharma raised Share XRoyalty Pharma shares surge 59% after $2.2 billion IPOhttps://pharmaphorum.com/news/royalty-pharma-shares-surge-59-after-2-2-billion-ipo/
Royalty Pharma plans largest IPO of the year so farRoyalty Pharma is planning the biggest IPO of the year as the market’s appetite for biotech stocks remains strong. Share XRoyalty Pharma plans largest IPO of the year so farhttps://pharmaphorum.com/news/royalty-pharma-plans-largest-ipo-of-the-year-so-far/
California’s AMT is latest biotech aiming to go public in pandemic IPO crazeCalifornia’s Applied Molecular Transport has become the latest biotech to go for an IPO during the pandemic, aiming Share XCalifornia’s AMT is latest biotech aiming to go public in pandemic IPO crazehttps://pharmaphorum.com/news/californias-amt/
ADC Therapeutics sets terms for $125m IPOSwiss cancer drugs firm ADC Therapeutics has set the terms for a $125 million IPO to further develop Share XADC Therapeutics sets terms for $125m IPOhttps://pharmaphorum.com/news/adc-therapeutics-sets-terms-for-125m-ipo/
BioNTech and Vir prepare mega-IPOs after flurry of launchesTwo of the largest-ever biotech initial public offerings (IPOs) are scheduled to go ahead in the coming week, Share XBioNTech and Vir prepare mega-IPOs after flurry of launcheshttps://pharmaphorum.com/news/biontech-and-vir-prepare-mega-ipos-after-flurry-of-launches/
Denmark’s Genmab prepares for $500m US IPOAntibody-based drugs firm Genmab, noted for developing the blood cancer drug Darzalex with Johnson & Johnson’s Janssen unit, Share XDenmark’s Genmab prepares for $500m US IPOhttps://pharmaphorum.com/news/denmarks-genmab-prepares-for-500m-us-ipo/
Digital health firms prepare for multi-billion dollar IPOsA gang of digital health start-ups worth a combined $7.6 billion are preparing for IPOs after three years Share XDigital health firms prepare for multi-billion dollar IPOshttps://pharmaphorum.com/news/digital-health-firms-prepare-for-multi-billion-dollar-ipos/
